Erythromycinestolate , ≥600units/mg , 3521-62-8

Synonym(s):
Erythromycin 2′-propionate dodecyl sulfate

CAS NO.：3521-62-8

Empirical Formula: C52H97NO18S

Molecular Weight: 1056.39

MDL number: MFCD00084691

EINECS: 222-532-4

PRODUCT Properties

• Melting point: 135-140°C dec.
• Boiling point: 743℃
• Density: 1.0053 (rough estimate)
• refractive index: 1.6550 (estimate)
• Flash point: >110°(230°F)
• storage temp.: Keep in dark place,Sealed in dry,Room Temperature
• solubility: chloroform: soluble4.0ML, clear, colorless (200 mg + 4.0 mL Chloroform)
• form: Solid
• pka: 6.9(at 25℃)
• color: white
• Water Solubility: Freely soluble in organic solvents, practically insoluble in water /n
• Sensitive: Light Sensitive

Description and Uses

Erythromycin estolate was synthesized by the Lilly Research Laboratories in 1959. It shows a higher and longer lasting serum level than erythromycin and the other esters, ethylsuccinate and stearate, when administered orally. This antibiotic is stable against gastric acids, and after oral absorption it is hydrolyzed gradually into erythromycin. Long-term usage of erythromycin estolate is toxic to the liver. Erythromycin ethylsuccinate [41342-53-4], (C43H75NO16, Mr 862.07) and erythromycin stearate [643-22-1] (C37H67NO13 · C18H36O2, Mr 1018.43) also have been used orally, and erythromycin lactobionate [3847-29-8] (C37H67NO13 · C12H22NO12, Mr 1092.25) has been used by intravenous administration and opthalmic topical application

Used as an antibacterial agent. LD50 >5000 mg/kg for oral administration to rats.

Safety

• Symbol(GHS): GHS07,GHS08
• Signal word: Danger
• Hazard statements: H302-H317-H334
• Precautionary statements: P261-P264-P280-P301+P312-P302+P352-P304+P340+P312
• Hazard Codes: Xn,Xi
• Risk Statements: 22-42/43-36/37/38
• Safety Statements: 22-36-26
• WGK Germany: 3
• RTECS: KF5775000
• HS Code: 29419000
• Toxicity: LD50 orally in rats: >5000 mg/kg (Goldenthal)